Trimethoprim

Trimethoprim

SCHEMBL958034

COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC.Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

folAfolP

The experimentally established mechanism targets of Trimethoprim. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DHFR P00374 3/20 0.63
MEN1 O00255 1/20 0.63
SLC22A1 O15245 1/20 0.63
ALDH1A1 P00352 1/20 0.63
CYP3A4 P08684 1/20 0.63
TSHR P16473 1/20 0.63
NFKB1 P19838 1/20 0.63
CYP2C19 P33261 1/20 0.63
BLM P54132 1/20 0.63
KMT2A Q03164 1/20 0.63
HSD17B10 Q99714 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetroxoprim SCHEMBL30075873 0.92
SCHEMBL9732799 0.88 DHFR (0.58) DHFRMEN1SLC22A1ALDH1A1CYP3A4
Trimethoprim SCHEMBL29420800 0.88 DHFR (0.59) DHFRMEN1SLC22A1ALDH1A1CYP3A4
Trimethoprim SCHEMBL9465189 0.87 ALDH1A1 (0.58) DHFRMEN1SLC22A1ALDH1A1CYP3A4
Trimethoprim SCHEMBL4731560 0.86 CYP2C19 (0.59) DHFRMEN1SLC22A1ALDH1A1CYP3A4
Trimethoprim SCHEMBL4182820 0.85 DHFR (0.72) DHFRMEN1SLC22A1ALDH1A1CYP3A4
Trimethoprim SCHEMBL28846304 0.85 DHFR (0.63) DHFRMEN1SLC22A1ALDH1A1CYP3A4
Trimethoprim SCHEMBL30345188 0.85 CYP2C19 (0.61) DHFRMEN1SLC22A1ALDH1A1CYP3A4
Trimethoprim SCHEMBL29674736 0.85 ESR1 (0.63) DHFRMEN1SLC22A1ALDH1A1CYP3A4
Trimethoprim SCHEMBL870329 0.85 ALDH1A1 (0.58) DHFRMEN1SLC22A1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415924-B1 METHOD FOR JOINING TWO SHEET-METAL PARTS TOGETHER BY ADHESIVE BONDING AND WELDING STELLANTIS AUTO SAS (FR) 2025-10-29 EP claimed
EP-4415924-A1 METHOD FOR JOINING TWO SHEET-METAL PARTS TOGETHER BY ADHESIVE BONDING AND WELDING Stellantis Auto SAS (FR) 2024-08-21 EP claimed
WO-2024155256-A1 A NEW ANTIMICROBIAL SUSCEPTIBILITY TEST KIT AND IN-VITRO METHOD SAKARYA ÜNİVERSİTESİ REKTÖRLÜĞÜ (TR) 2024-07-25 WO claimed
CN-116098909-B Sulfadimidine trimethoprim suspension and preparation method thereof 中牧全药(南京)动物药品有限公司 2024-05-24 CN claimed
WO-2023062296-A1 METHOD FOR JOINING TWO SHEET-METAL PARTS TOGETHER BY ADHESIVE BONDING AND WELDING PSA AUTOMOBILES SA (FR) 2023-04-20 WO claimed
US-20160287528-A1 METHODS AND COMPOSITIONS FOR USE IN AQUACULTURE CHEMAPHOR INC. (CA) 2016-10-06 US claimed
US-20130156816-A1 METHODS AND COMPOSITIONS FOR USE IN AQUACULTURE CHEMAPHOR INC. (CA) 2013-06-20 US claimed
EP-2536293-A1 METHODS AND COMPOSITIONS FOR USE IN AQUACULTURE Chemaphor Inc. (CA) 2012-12-26 EP claimed
WO-2011103464-A1 METHODS AND COMPOSITIONS FOR USE IN AQUACULTURE CHEMAPHOR INC. (CA) 2011-08-25 WO claimed
US-20260094617-A1 METHOD OF PROCESSING MULTIMEDIA, ELECTRONIC DEVICE, AND STORAGE MEDIUM BEIJING ZITIAO NETWORK TECHNOLOGY CO LTD (CN) 2026-04-02 US disclosed
US-12545739-B2 Compositions and methods for making and using bispecific antibodies UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-02-10 US disclosed
EP-4415924-B1 METHOD FOR JOINING TWO SHEET-METAL PARTS TOGETHER BY ADHESIVE BONDING AND WELDING STELLANTIS AUTO SAS (FR) 2025-10-29 EP disclosed
US-20250325579-A1 COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING SYNEDGEN INC (US) 2025-10-23 US disclosed
US-20250261677-A1 Confirming Diethylcarbamazine Levels using Near-Infrared Spectroscopy Detection in an Extruder RUBICON SCIENTIFIC, LLC (US) 2025-08-21 US disclosed
US-8337897-B2 Immediate release pharmaceutical granule compositions and a continuous process for making them UNIVERSITEIT GENT (BE) 2012-12-25 US disclosed
US-20110240504-A1 METHOD AND APPARATUS FOR PACKAGING AND DISPENSING PHARMACEUTICALS APOTEX TECHNOLOGIES INC. (CA) 2011-10-06 US disclosed
WO-2011103464-A1 METHODS AND COMPOSITIONS FOR USE IN AQUACULTURE CHEMAPHOR INC. (CA) 2011-08-25 WO disclosed
US-7927613-B2 Pharmaceutical co-crystal compositions UNIVERSITY OF SOUTH FLORIDA (US) 2011-04-19 US disclosed
US-20110008454-A1 IMMEDIATE RELEASE PHARMACEUTICAL GRANULE COMPOSITIONS AND A CONTINUOUS PROCESS FOR MAKING THEM UNIVERSITEIT GENT (BE) 2011-01-13 US disclosed
WO-1998010774-A2 USE OF OZONE FOR TREATING DISEASES OF BODY CAVITY TISSUES, AND APPARATUS THEREFORE RID (RISKIN DEVICES) LTD. (IL) 1998-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545739-B2 Compositions and methods for making and using bispecific antibodies TNFRSF9, TNFRSF1A, FOLR1 DHFR 12/4885MEN1 1913/4885SLC22A1 1336/4885
US-20260094617-A1 METHOD OF PROCESSING MULTIMEDIA, ELECTRONIC DEVICE, AND STORAGE MEDIUM ELMO1, MTREX, RNMT DHFR 3087/4885MEN1 1538/4885SLC22A1 4360/4885
US-20250325579-A1 COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING PARG, ARGLU1, AREG DHFR 3163/4885MEN1 3976/4885SLC22A1 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.